诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评,即将惠及国内广大MASH患者

药研途
Mar 06

2026年3 月 3 日,CDE 官网显示,诺和诺德“司美格鲁肽注射液”新适应症在国内申报上市,并拟纳入优先审评,适应症为:用于治疗代谢相关脂肪性肝炎(MASH)伴中重度肝纤维化(符合 F2-F3 期纤维化)的非肝硬化成人患者。代谢功能障碍相关脂肪性肝炎(Metabolic Dysfunction-Associated Steatohepatitis,MASH)是代谢功能障碍相关脂肪性肝病(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10